TGFB1 and prostate carcinoma: Our preliminary research found that, despite the high activation of immunosuppressive pathways such as TGF-β and the infiltration of numerous immune cells in C2 subtype prostate cancer samples, these samples still exhibited a favorable response rate to immunotherapy.